Alumis ALMS
NASDAQ ALMS
$9.90 +0.10 (+1.02%)
At close: Sep 10, 2026 · 4:00 PM EDT

Alumis (ALMS) Income towards Parent Company (2023 - 2026)

Alumis' (ALMS) quarterly Income towards Parent Company came in at -$142.2 million in Q2 2026, down 339.52% year-over-year from $59.4 million in Q2 2025, and down 192.34% quarter-over-quarter from -$48.6 million in Q4 2025.

Analysis

Alumis (ALMS) Income towards Parent Company (2023 - 2026) Analysis & Trends

Alumis (ALMS) has reported Income towards Parent Company for 4 consecutive years, with -$142.2 million the latest figure, recorded in Q2 2026.

  • On a quarterly basis, Income towards Parent Company fell 339.52% year-over-year to -$142.2 million in Q2 2026; TTM through Jun 2026 was -$242.2 million, a 43.95% decrease from a year earlier, with the FY2025 full-year figure at -$199.0 million, up 14.39% from the prior year.
  • Income towards Parent Company was -$142.2 million for Q2 2026 at Alumis, down from -$48.6 million in the prior quarter.
  • Over five years, Income towards Parent Company peaked at $59.4 million in Q2 2025 and troughed at -$142.2 million in Q2 2026.
  • A 4-year average of -$57.9 million and a median of -$48.1 million in 2024 frame the typical range for Income towards Parent Company.
  • Across the five-year window, Income towards Parent Company surged 205.05% in 2025 and sank 339.52% in 2026, its largest moves.
  • Over 4 years, Income towards Parent Company stood at -$40.1 million in 2023, then increased by 17.85% to -$33.0 million in 2024, then slumped by 47.51% to -$48.6 million in 2025, then sank by 192.34% to -$142.2 million in 2026.
  • The last three Income towards Parent Company figures came in at -$142.2 million (Q2 2026), -$48.6 million (Q4 2025), and -$110.8 million (Q3 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Alumis 1.27 Bn 765.76 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 -142.18 Mn
Dec 31, 2025 -48.64 Mn
Sep 30, 2025 -110.75 Mn
Jun 30, 2025 59.36 Mn
Mar 31, 2025 -101.53 Mn
Dec 31, 2024 -32.97 Mn
Sep 30, 2024 -93.12 Mn
Jun 30, 2024 -56.51 Mn
Mar 31, 2024 -47.59 Mn
Dec 31, 2023 -40.13 Mn
Sep 30, 2023 -43.76 Mn
Jun 30, 2023 -36.71 Mn